








































































































































































































































































































































































































































































Tumour	elevation	(mm)	 9.16	±	0.49	 NA	 0.337	
















































































































Age	of	presentation	(mm)	 -0.024	 (-0.053)-0.004	 0.093	
Foveal	Rb	(yes	vs.	no)	 0.363	 (-0.559)-1.285	 0.426	
TTT	(yes	vs.	no)	 0.664	 0.175-1.153	 0.010	


















1	 D/D	 cT2bN0M0H1/cT2bN0M0H1	 19.6	 Leukocoria	 0.9	 Enucleated	 Nil	 NA	
2	 D/D	 cT2bN0M0H1/cT2bN0M0H1	 4.4	 Leukocoria	 1	 1.1	 Yes	 Alt	ET	
3	 D/D	 cT2bN0M0H1/cT2bN0M0H1	 2.5	 Leukocoria	 2.3	 Enucleated	 Yes	 NA	
4	 B/D	 cT1bN0M0H1/cT2bN0M0H1	 14.8	 Strabismus	 0.08	 1.3	 Nil	 LXT,	LHoT,	LIO	u/a	
5	 E/D	 cT3cN0M0H1/cT2bN0M0H1	 9.9	 Strabismus	 Enucleated	 0.7	 Nil	 NA	
6	 D/D	 cT2bN0M0H1/cT2aN0M0H1	 23.7	 Strabismus	 0.3	 Enucleation	 Nil	 NA	
7	 D/D	 cT2bN0M0H1/cT2bN0M0H1	 4.6	 Leukocoria	 0.1	 -0.2	 Nil	 RX(T)	
8	 0/D	 cT0N0M0H0/cT2aN0M0H0	 1.6	 Leukocoria	 -0.06	 1.8	 Nil	 LXT	
9	 C/D	 cT2bN0M0H1/cT2aN0M0H1	 2.3	 Leukocoria	 0.1	 1.8	 Nil	 Nil	
10	 D/C	 cT2aN0M0H1/cT2bNoMoH1	 10.8	 Leukocoria	+	strabismus	 2.6	 0.02	 Nil	 Nil	
11	 D/E	 cT2bN0M0H1/cT3cN0M0H1	 17.7	 Leukocoria	+	strabismus	 0.88	 Enucleated	 Yes	 NA	
12	 D/D	 cT2bN0M0H1/cT2bN0M0H1	 5.9	 Leukocoria	 1.2	 1.2**	 Yes	 Alt	XT	
13	 0/D	 cT0N0M0H0/cT2bN0M0H0	 12.6	 Strabismus	 0.04	 1.12	 Nil	 LXT	
14	 0/D	 cT0N0M0H0/cT2bN0M0H0	 11.7	 Leukocoria	 0	 2.08	 Nil	 LXT	
15	 D/D	 cT2aN0M0H1/cT2aN0M0H1	 11.4	 Nystagmus	 1.3	 0.4	 Yes	 RXT	
16	 D/D	 cT2bN0M0H1/cT2bN0M0H1	 11.1	 Strabismus	 2.08	 0.5	 Nil	 RXT	
17	 E/D	 cT3bN0M0H1/cT2bN0M0H1	 3.6	 Leukocoria	 Enucleated	 1.38	 Yes	 NA	
18	 D/C	 cT2bN0M0H1/cT2bN0M0H1	 16.4	 Strabismus	 0.9	 Enucleated	 Nil	 NA	
19	 D/A	 cT2bN0M0H1/cT1aN0M0H1	 1.9	 Strabismus	 2.6	 0.1	 Nil	 RXT	
20	 0/D	 cT0N0M0H0/cT2bN0M0H0	 13.1	 Leukocoria	 0	 1.78	 Nil	 LXT	
21	 0/D	 cT0N0M0H0/cT2bN0M0H0	 7.3	 Leukocoria	 0	 0.26	 Nil	 Nil	
22	 D/D	 cT2bN0M0H1/cT2aN0M0H1	 19.3	 Leukocoria	 0.9	 0.16	 Nil	 RET	
23	 D/0	 cT2bN0M0H0/cT0N0M0H0	 50.4	 Leukocoria	 0.1	 0	 Nil	 Nil	
24	 D/0	 cT2bN0M0H1/cT0N0M0H1	 15.1	 Leukocoria	 0.62	 -0.02	 Nil	 Nil	
25	 D/A	 cT2bN0M0H1/cT1aN0M0H1	 9.5	 Leukocoria	 2.6	 0.2	 Nil	 RXT	
26	 0/D	 cT0N0M0H1/cT2bN0M0H1	 12.1	 Strabismus	 0	 2.3	 Nil	 LXT	
27	 D/0	 cT2bN0M0H0/cT0N0M0H0	 32.9	 Leukocoria	+	strabismus	 0.14	 -0.02	 Nil	 RET,	RSO	palsy,	RHT	
	–exotropia,	HoT		–esotropia,	XT		–alternate,	ET		–applicable,	Alt	-non	–left,	NA		–right,	L		–R		7International	Intraocular	Retinoblastoma	Classification,	–IIRC	
hypotropia,	IO	–	inferior	oblique,	u/a	–	under	action,	X(T)	–	intermittent	exotropia,	SO	–	superior	oblique,	HT	–	hypertropia.		
term	Orthoptic	Outcomes	in	Group	D	Retinoblastoma-gnLo	/et	al.		Fabian	
	
24.staging	systemedition	AJCC/UICC	clinical		th8	*	
**	Less	than	12	months	of	follow-up	since	last	treatment,	hence	not	included	for	visual	outcomes	analysis.		
	
